Apollo Medical price target raised to $60 from $40 at Lake Street

Lake Street analyst Brooks O’Neil raised the firm’s price target on Apollo Medical to $60 from $40 and keeps a Buy rating on the shares after the company reported "strong" Q4 results and gave 2023 guidance that was above the firm’s forecast and consensus. With shares trading at what the firm sees as "a meaningful discount to some logical peers in the value-based care market," Lake Street sees "a meaningful opportunity" for Apollo Medical investors at current levels.